Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Morizane T YM, Kojimahara N et al (2014) Minds Handbook for Clinical Practice Guideline Development 2014. Japan Council for Quality Health Care, Tokyo
2. Kojimahara N NT, Morizane T et al (2017) Minds Manual for Guideline Development 2017. Japan Council for Quality Health Care, Tokyo
3. Loibl S, Mueller V, von Minckwitz G et al (2011) Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 19(11):1789–1795
4. Kahl C, Sayer HG, Hinke A et al (2012) Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 138(3):513–517
5. Lambertini M, Bruzzi P, Poggio F et al (2016) Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. Support Care Cancer 24(3):1285–1294